comparemela.com

Latest Breaking News On - முடிவுகள் ப்ரெஸெஂடெட் - Page 1 : comparemela.com

Systemanalyse und Hardware-Diagnose: Prüft umfangreich euren PC | 12 kostenlose Downloads

Systemanalyse und Hardware-Diagnose: Prüft umfangreich euren PC | 12 kostenlose Downloads
netzwelt.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from netzwelt.de Daily Mail and Mail on Sunday newspapers.

Unterföhring - Brückenschlag über die Isar - Landkreis München

Unterföhring - Brückenschlag über die Isar - Landkreis München
sueddeutsche.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sueddeutsche.de Daily Mail and Mail on Sunday newspapers.

INPACT AV Drug-Coated Balloon Is First And Only To Show Superior And Sustained Results Through Two Years Compared To PTA In Treating Arteriovenous Fistulae Lesions

INPACT AV Drug-Coated Balloon Is First And Only To Show Superior And Sustained Results Through Two Years Compared To PTA In Treating Arteriovenous Fistulae Lesions
meddeviceonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meddeviceonline.com Daily Mail and Mail on Sunday newspapers.

IN PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Share this article Share this article IN.PACT AV Access Trial 24 Month Results Presented as a Podium First at Charing Cross Symposium DUBLIN and LONDON, April 20, 2021 /PRNewswire/ Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study. The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.